Tri-fused ring compound and application thereof

By using triangular cyclic compounds as IRAK4 degrading agents, IRAK4 protein is degraded using PROTAC technology, solving the problem that kinase inhibitors in the prior art cannot completely block the inflammatory response, and achieving efficient IRAK4 degradation and anti-tumor effects.

CN119019427AActive Publication Date: 2024-11-26TAINUORUI (TIANJIN) BIOTECHNOLOGY CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411115570.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26
Estimated Expiration
2044-08-14

AI Technical Summary

Technical Problem

Existing IRAK4 small molecule kinase inhibitors can only inhibit kinase activity and cannot completely block the generation of inflammatory response signals. They also have target drug resistance problems.

Method used

A triad cyclic compound was developed as an IRAK4 degrader, and the IRAK4 protein was degraded through the ubiquitin protease system using PROTAC technology to block its kinase activity and scaffold function.

Benefits of technology

Significant degradation of IRAK4 was achieved, and half of the degradation concentration of some compounds reached the nanomolar level, which significantly inhibited inflammatory response and anti-tumor activity, and overcome the drug resistance problem of small molecule drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019427A_ABST
    Figure CN119019427A_ABST
Patent Text Reader

Abstract

The invention provides a tri-fused ring compound and application thereof. The tri-fused ring compound has a structure as shown in a formula I. The invention further provides a preparation method of the tri-fused ring compound. The tricyclic compound has remarkable degradation activity on IRAK4 in cells, and can be used for preparing medicines for treating and / or preventing related diseases or symptoms mediated by the IRAK4.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug synthesis, and relates to a tricyclic compound and an application thereof, and in particular to a tricyclic IRAK4 degradation agent and an application thereof. Background Art

[0002] Interleukin-1 receptor kinase 4 (IRAK4) is one of the isozymes of the intracellular serine-threonine kinase IRAK protein family. It is a key node in the downstream signaling pathways of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs), and plays an important role in the immune system. Its overactivation or abnormal activation due to mutations is involved in the occurrence and development of inflammatory diseases and tumors.

[0003] TLR and IL-1R use the conserved TLR / IL-1R (TIR) ​​domain together to recruit the adaptor protein MyD88 in the cell, and MyD88 continues to recruit IRAK4 to form the Myddosome. In the Myddosome, IRAK4 is activated by trans-autophosphorylation, and then activates a series of transcription factors downstream, such as NF-κB, CREB, AP-1, IRF, etc., to promote the secretion of pro-inflammatory cytokines, the proliferation and differentiation of immune cells, etc. Therefore, IRAK4 plays an important role in the onset and progression of inflammatory diseases.

[0004] Dysregulation of the TLR / IL-1R signaling pathway is also closely related to the occurrence and progression of cancer. Mutations in proteins in the TLR / IL-1R pathway may lead to overactive signals and increased NF-κB activity, and promote cancer.

[0005] IRAK4 mediates the IL-1R / TLR downstream signaling pathway and participates in immune monitoring through two pathways: on the one hand, IRAK4 has kinase activity and can phosphorylate downstream proteins IRF5 / 7; on the other hand, IRAK4 plays a scaffolding role and is responsible for forming the protein multimer myddosome complex. Although there are many IRAK4 small molecule kinase inhibitors in the prior art, they can only inhibit the activity of the kinase itself, showing moderate efficacy, and cannot destroy the formation of the complex to completely block the generation of inflammatory response signals.

[0006] Targeted protein degradation (TPD) is an emerging treatment method that has attracted much attention because it can regulate proteins that are difficult to target with traditional small molecules. Protein degradation targeted chimeras (PROTACs) use the natural protein degradation system in cells, the ubiquitin protease system (UPS), to achieve targeted degradation of target proteins (POIs). PROTACs are heterobifunctional small molecules that target POIs at one end and recruit E3 ubiquitin ligases at the other end to form a ternary complex. POIs are tagged with ubiquitin and then recognized and degraded by the proteasome.

[0007] Compared with traditional small molecule drugs, PROTAC molecules have the following advantages: (1) They have catalytic degradation function. Unlike each small molecule inhibitor that can only act on one protein molecule, each PROTAC molecule can degrade many protein molecules, so a very low dose can have a good efficacy; (2) They work by degrading the target protein, so they can overcome the problem of small molecule drug resistance caused by increased target protein expression, and can also block the non-enzyme function of the target. Therefore, in view of the characteristics of IRAK4 that has both kinase activity and scaffold function, the use of PROTAC technology can degrade IRAK4 protein, block kinase activity and destroy the target protein scaffold function at the same time, and achieve complete inhibition of the pathway compared to conventional kinase inhibitors, resulting in better inhibition of inflammatory response or anti-tumor activity. Therefore, in this field, the further development of such molecules is of great significance. Summary of the invention

[0008] In view of the deficiencies in the prior art, the object of the present invention is to provide a tricyclic compound and its application, in particular to provide a tricyclic IRAK4 degrader and its application.

[0009] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0010] In one aspect, the present invention provides a tricyclic compound, a stereoisomer, a geometric isomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein the tricyclic compound has a structure as shown in the following formula I:

[0011]

[0012] in:

[0013] It is expressed as a single bond or a double bond, provided that the valence requirements are met;

[0014] A is a 6-10 membered aryl group or a 5-10 membered heteroaryl group;

[0015] B is a substituted or unsubstituted C2-C4 alkyl group, a substituted or unsubstituted 4-10 membered cycloalkyl group, or a substituted or unsubstituted 4-10 membered heterocycloalkyl group;

[0016] C is a substituted or unsubstituted C2-C4 alkyl group, a substituted or unsubstituted 4-10 membered cycloalkyl group, or a substituted or unsubstituted 4-10 membered heterocycloalkyl group;

[0017] One of X and Y is a nitrogen atom and the other is a carbon atom;

[0018] Z is CH2 or C=O;

[0019] R a Each is independently selected from hydrogen, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, di(C1-C4 alkyl)amino, 5-10 membered cycloalkyl, 5-10 membered heterocycloalkyl;

[0020] m is an integer from 0 to 5 (e.g., 0, 1, 2, 3, 4 or 5);

[0021] R b Selected from C1-C4 alkoxy, C3-C6 cycloalkyloxy or R1 and R2 are each independently selected from C1-C4 alkyl groups, and the wavy line represents the attachment point of the group.

[0022] In the present invention, the substituent in the substituted group as described above is selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl or -O-(C1-C6 alkyl).

[0023] In the present invention, the 6-10 membered aryl group may be a 6-, 7-, 8-, 9- or 10-membered aryl group, the 5-10 membered heteroaryl group may be a 5-, 6-, 7-, 8-, 9- or 10-membered heteroaryl group, the 4-10 membered cycloalkyl group may be a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered cycloalkyl group, the 5-10 membered heterocycloalkyl group may be a 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group, the C2-C4 alkyl group may be a C2, C3 or C4 alkyl group, the C1-C4 alkyl group may be a C1, C2, C3 or C4 alkyl group, and the C3-C6 cycloalkyloxy group may be a C3, C4, C5 or C6 cycloalkyloxy group.

[0024] Preferably, the ring A is The wavy line represents the attachment site of the group.

[0025] Preferably, the B structure is Or -CH2CH2-, the wavy line represents the attachment site of the group.

[0026] Preferably, the C structure is -CH2-, -CH2CH2- or -CH2CH2CH2-, the wavy line represents the attachment site of the group.

[0027] Preferably, Ra are each independently selected from hydrogen, fluorine, chlorine, cyano, trifluoromethyl, trifluoromethoxy, The wavy line represents the attachment site of the group.

[0028] Preferably, Selected from The wavy line represents the attachment site of the group.

[0029] Preferably, R b is selected from methoxy, ethoxy, isopropoxy, cyclopropyloxy or In any of the above, the wavy line represents the attachment site of the group.

[0030] Preferably, the compound of formula I of the present invention is selected from any one of the compounds of the following structures:

[0031]

[0032]

[0033]

[0034]

[0035] Preferably, the pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, hydrochlorides, hydrobromides, hydroiodides, acetates, propionates, caprates, octanoates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyrates, any one of the following salts: -1,4-dioic acid salt, hexyne-1,6-dioic acid salt, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate or mandelate.

[0036] On the other hand, the present invention provides a tricyclic IRAK4 degrader, which includes the tricyclic compound as described above, its stereoisomers, geometric isomers, tautomers or pharmaceutically acceptable salts.

[0037] In another aspect, the present invention provides a pharmaceutical composition comprising the tricyclic compound as described above, its stereoisomers, geometric isomers, tautomers or pharmaceutically acceptable salts.

[0038] On the other hand, the present invention provides the use of the tricyclic compound as described above, its stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt or the pharmaceutical composition in the preparation of a drug for treating a disease or condition mediated by IRAK4.

[0039] Preferably, the disease comprises an inflammatory disease, an autoimmune disease or a tumor.

[0040] Preferably, the inflammatory disease is selected from Crohn's disease, ulcerative colitis, asthma, graft-versus-host disease, chronic obstructive pulmonary disease, atopic dermatitis, gout, gouty arthritis, conjunctivitis, hepatitis, chronic inflammatory lung disease, thyroiditis or interstitial cystitis.

[0041] Preferably, the autoimmune disease is selected from Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, psoriasis, psoriatic arthritis, cryptopyrin-associated periodic syndrome, TNF receptor-associated periodic syndrome, multiple sclerosis, allergic rhinitis, scleroderma, dermatomyositis, vasculitis or nephritis.

[0042] Preferably, the tumor is selected from lung cancer, breast cancer, prostate cancer, pancreatic cancer, kidney cancer, liver cancer, gastrointestinal cancer, cervical cancer, endometrial cancer, testicular cancer, genitourinary tract cancer, colorectal cancer, laryngeal cancer, skin cancer, bone cancer, head and neck tumors, sarcoma, brain tumor, glioblastoma, melanoma, multiple myeloma, lymphoma or leukemia.

[0043] Compared with the prior art, the present invention has the following beneficial effects:

[0044] The compounds of the present invention have significant degradation ability for IRAK4 in THP1-HIBiT-IRAK4 cells. The half degradation concentration (DC 50 ) can reach the nanomolar level; the results of Western blotting experiments also showed that the compounds of the present invention have strong degradation activity on IRAK4 protein in OCI-LY10 cells at concentrations of 100nM and 1000nM. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 This is a graph showing the Western blot results of the compound of Example 1 at concentrations of 100 nM and 1000 nM on the degradation of IRAK4 protein in OCI-LY10 cells.

[0046] Figure 2This is a graph showing the Western blot results of Example 2 compound at concentrations of 100 nM and 1000 nM for the degradation of IRAK4 protein in OCI-LY10 cells.

[0047] Figure 3 This is a graph showing the Western blot results of Example 3 compound at concentrations of 100 nM and 1000 nM on IRAK4 protein degradation in OCI-LY10 cells.

[0048] Figure 4 This is a Western blot result of Example 4 compound at concentrations of 100 nM and 1000 nM on IRAK4 protein degradation in OCI-LY10 cells.

[0049] Figure 5 This is a Western blot result of Example 5 compound at concentrations of 100 nM and 1000 nM on IRAK4 protein degradation in OCI-LY10 cells.

[0050] Figure 6 This is a graph showing the Western blot results of Example 6 compound at concentrations of 100 nM and 1000 nM for the degradation of IRAK4 protein in OCI-LY10 cells.

[0051] Figure 7 This is a graph showing the Western blot results of Example 7 compound at concentrations of 100 nM and 1000 nM on IRAK4 protein degradation in OCI-LY10 cells.

[0052] Figure 8 This is a graph showing the Western blot results of Example 8 compound at concentrations of 100 nM and 1000 nM for the degradation of IRAK4 protein in OCI-LY10 cells.

[0053] Fig. 9 This is a Western blot result of the compound of Example 9 at concentrations of 100 nM and 1000 nM on the degradation of IRAK4 protein in OCI-LY10 cells.

[0054] Fig.10 The figure is a Western blot result of Example 10 compound at concentrations of 100 nM and 1000 nM on IRAK4 protein degradation in OCI-LY10 cells.

[0055] Fig.11 This is a graph showing the Western blot results of Example 11 compound at concentrations of 100 nM and 1000 nM on IRAK4 protein degradation in OCI-LY10 cells.

[0056] Fig.12This is a graph showing the Western blot results of Example 12 compound at concentrations of 100 nM and 1000 nM on IRAK4 protein degradation in OCI-LY10 cells.

[0057] Fig.13 This is a graph showing the Western blot results of Example 13 compound at concentrations of 100 nM and 1000 nM on IRAK4 protein degradation in OCI-LY10 cells. DETAILED DESCRIPTION

[0058] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0059] In the following examples, unless otherwise noted by structural formula or chemical name, molecules with a single chiral center exist as racemic mixtures. Unless otherwise noted by structural formula or chemical name, those molecules with two or more chiral centers exist as racemic mixtures of diastereomers. Single enantiomers / diastereomers can be obtained by methods known to those skilled in the art.

[0060] Preparation method

[0061] The compounds described in the present invention can be synthesized according to the synthetic methods described herein and / or techniques well known in the art.

[0062] Preparation Example

[0063] The compounds described herein can be synthesized according to one or more synthesis schemes and / or techniques well known in the art. It will be appreciated by those skilled in the art that the synthesis methods of certain embodiments described in detail in the present invention can be easily adapted to synthesize other embodiments. In some embodiments, the compounds described herein can be prepared by an appropriate combination of synthesis methods well known in the art. Many starting materials and other reagents can be purchased from commercial suppliers, such as Alfa Aesar (China) Chemical Co., Ltd., or easily prepared using synthesis methods commonly used in the art.

[0064] 1 H NMR spectra were recorded on an instrument operating at 400 MHz. 1 HNMR spectra were obtained as solutions (reported in ppm). When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), dd (doublet of doublets), dt (doublet of triplets). Coupling constants are given in Hertz (Hz).

[0065] If desired, (R)- and (S)-isomers of the non-limiting exemplary compounds, if present, can be resolved by methods known to those skilled in the art, such as by forming diastereomeric salts or complexes, which can be separated by, for example, crystallization; by forming diastereomeric derivatives, which can be separated by, for example, crystallization or chromatography; by selectively reacting one enantiomer with an enantiomer-specific reagent, followed by separation of the modified and unmodified enantiomers; or by chromatographic separation in a chiral environment, such as a chiral chromatographic column. Alternatively, a specific enantiomer can be prepared by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.

[0066] Preparation of compounds:

[0067] Key intermediate IM-1:

[0068]

[0069] Step 1: Synthesis of IM-1a

[0070]

[0071] Dissolve N-Boc-propargyl ammonium (50.0 g, 322 mmol, 1.00 eq) in N,N-dimethylformamide (500 mL), cool the system to 0 ° C, slowly add sodium hydride (15.4 g, 386 mmol, 60% mineral oil dispersion, 1.20 eq) to the system at 0 ° C in batches, and add it over 30 minutes. Warm the system to 25 ° C and stir for 1 hour. Then add 3-bromopropyne (53.6 g, 451 mmol, 38.8 mL, 1.40 eq) to the reaction system at 25 ° C, and stir the reaction at 25 ° C for 1.5 hours. The reaction is quenched with ice water (500 mL) and extracted with ethyl acetate (600 ml * 3). The combined organic phase is dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 0 / 1) to obtain compound IM-1a (40.0 g, 206 mmol) as a yellow oil.

[0072] Step 2: Synthesis of IM-1b

[0073]

[0074] Compound IM-1a (23.0 g, 119 mmol, 1.00 eq) and dimethyl butynedioate (16.9 g, 119 mmol, 1.00 eq) were dissolved in ethanol (230 mL), and tris(triphenylphosphine)rhodium chloride (1.10 g, 1.19 mmol, 0.01 eq) was added to the reaction system under nitrogen protection at 25°C. The reaction was heated to 80°C and stirred at 80°C for 12 hours. The reaction mixture was filtered under reduced pressure and concentrated. The obtained residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 0 / 1) to obtain compound IM-1b as a dark brown solid (4.00 g).

[0075] Step 3: Synthesis of IM-1c

[0076]

[0077] Compound IM-1b (3.50 g, 10.4 mmol, 1.00 eq) was dissolved in ethanol (35.0 mL), sodium hydroxide solution (3.00 M, 17.3 mL, 5.00 eq) was added to the reaction system at 25 ° C, the reaction was heated to 80 ° C and stirred at 80 ° C for 12 hours. The reaction was concentrated under reduced pressure, the mixture was dissolved in water (30.0 mL) and ethyl acetate (30.0 mL), the organic layer was separated, and then the aqueous layer was acidified to pH = 4 with 1N dilute hydrochloric acid in an ice bath. The aqueous layer was extracted with ethyl acetate (50.0 mL * 3). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound IM-1c as a dark brown solid (3.00 g, crude product).

[0078] Step 4: Synthesis of IM-1d

[0079]

[0080] Compound IM-1c (3.00 g, 9.76 mmol, 1.00 eq) was dissolved in acetic anhydride (40.0 mL) at 25 °C, the reaction was heated to 80 °C and stirred at 80 °C for 12 hours. The reaction mixture was quenched with 50 mL of water at 25 °C, and then extracted with ethyl acetate (50.0 mL*3). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 0 / 1) to obtain compound IM-1d as a white solid (2.00 g).

[0081] Step 5: Synthesis of IM-1e

[0082]

[0083] Compound IM-1d (2.00 g, 6.91 mmol, 1.00 eq) and 3-amino-2,6-piperidindione hydrochloride (1.25 g, 7.61 mmol, 1.10 eq) were added to toluene (20.0 mL). Triethylamine (2.10 g, 20.7 mmol, 2.89 mL, 3.00 eq) was added to the reaction system at 25 °C, the reaction was heated to 60 °C and stirred at 60 °C for 12 hours. 20 mL of water was added at 25 °C to quench the reaction mixture, and then extracted with ethyl acetate (30.0 mL*3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by high performance liquid chromatography (formic acid system) to obtain compound IM-1e as a white solid (1.00 g, 2.50 mmol).

[0084] 1 HNMR: (400MHz, DMSO-d6) δ11.12(s,1H),7.89(d,J=2.4Hz,2H),5.15(dd,J=5.4,13.0Hz,1H),4.72(br d,J=9.7Hz,4H),2.80-2.97(m,1H),2.53-2.65(m,2H),2.02-2.12(m,1H),1.47(s,9H).

[0085] Step 6: Synthesis of IM-1

[0086]

[0087] Compound IM-1e (100 mg, 250 μmol, 1.00 eq) was dissolved in dioxane (1.00 mL), and hydrochloric acid / dioxane (4.00 M, 250 μL, 4.00 eq) was added to the reaction system at 25° C. The reaction mixture was stirred at 25° C. for 12 hours and then concentrated under reduced pressure to obtain compound IM-1 (80.0 mg, hydrochloride) as a white solid.

[0088] Key intermediate IM-2:

[0089]

[0090] Step 1: Synthesis of IM-2a

[0091]

[0092] Compound IM-1e (1.00 g, 2.50 mmol, 1.00 eq) was dissolved in glacial acetic acid (10.0 mL), zinc powder (1.45 g, 22.1 mmol, 8.86 eq) was added at 25°C, and the reaction system was heated to 60°C and stirred for 12 hours. The mixture was filtered, washed with ethyl acetate, and the filtrate was concentrated under reduced pressure to obtain compound IM-2a (1.00 g, crude product) as a reddish brown solid.

[0093] LCMS: m / z=346.1 [M-55].

[0094] Step 2: Synthesis of IM-2b

[0095]

[0096] Compound IM-2a (1.00 g, 2.49 mmol, 1.00 eq) was dissolved in dichloromethane (10.0 mL), trifluoroacetic acid (1.70 g, 14.9 mmol, 1.11 mL, 6.00 eq) and triethylsilane (2.90 g, 24.9 mmol, 3.98 mL, 10.0 eq) were added to the system at 25 ° C, and the mixture was stirred at 25 ° C for 2 hours. The mixture was concentrated in vacuo to obtain compound IM-2b (900 mg, crude product) as a dark brown solid.

[0097] LCMS: m / z = 386.2 [M+H + ].

[0098] Step 3: Synthesis of IM-2

[0099]

[0100] Compound IM-2b (500 mg, 1.30 mmol, 1.00 eq) was dissolved in dichloromethane (5.00 mL), trifluoroacetic acid (890 mg, 7.84 mmol, 584 μL, 6.00 eq) was added to the reaction system under nitrogen protection at 25°C, and the reaction was stirred at 25°C for 4 hours. The reaction solution was filtered and concentrated under reduced pressure to obtain compound IM-2 (500 mg, crude trifluoroacetate) as a dark brown solid. LCMS: m / z = 286.2 [M+H + ].

[0101] Key intermediate IM-3:

[0102]

[0103] first step:

[0104]

[0105] Tert-butyl 4-(2-bromoacetyl)piperidine-1-formate (25.0 g, 81.6 mmol) and methyl 2-amino-5-bromoisonicotinate (18.8 g, 81.6 mmol) were dissolved in acetonitrile (150 mL) and toluene (100 mL). Sodium bicarbonate (13.6 g, 163 mmol) was added to the mixture at 25 ° C. The reaction mixture was heated to 90 ° C and stirred at 90 ° C for 12 hours. Thin layer chromatography showed that the reaction was complete. The reaction mixture was poured into ice water (500 mL) and stirred for 10 minutes. The aqueous phase was extracted with ethyl acetate (300 mL × 3). The combined organic phase was washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Purified by column chromatography (silica gel, petroleum ether / ethyl acetate volume ratio = 100 / 1 to 0 / 1) to obtain compound IM-3a as a dark brown solid (20.0 g).

[0106] Step 2:

[0107]

[0108] Compound IM-3a (20.0 g, 45.6 mmol) and 6-(trifluoromethyl)pyridine-2-carboxamide (26.0 g, 136 mmol) were dissolved in dioxane (200.0 mL), and cesium carbonate (29.7 g, 90.7 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (10.5 g, 18.2 mmol) and palladium acetate (2.04 g, 9.13 mmol) were added to the reaction mixture under nitrogen protection at 25°C. The reaction mixture was heated to 100°C and stirred at 100°C for 12 hours. The reaction mixture was cooled to 25°C and concentrated under reduced pressure. The residue was poured into ice water (300 mL) and stirred for 5 minutes. The aqueous phase was extracted with ethyl acetate (300 mL×3), and the combined organic phase was washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate volume ratio = 100 / 1 to 0 / 1) to obtain compound IM-3b as a yellow solid (10.0 g).

[0109] Step 3:

[0110]

[0111] Compound IM-3b (10.0 g, 18.1 mmol) was dissolved in tetrahydrofuran (100 mL), the reaction mixture was cooled to 0 ° C, methylmagnesium bromide (3M, 36.5 mL) was slowly added dropwise, and the system was slowly heated to 25 ° C and stirred at 25 ° C for 3 hours. The reaction was quenched with aqueous ammonium chloride solution (200 mL), extracted with ethyl acetate (3×100 mL), and the combined organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate volume ratio = 100 / 1 to 0 / 1) to obtain compound IM-3c as a white solid (4.00 g, crude product).

[0112] Step 4:

[0113]

[0114] Dissolve compound IM-3c (4.00 g, 7.32 mmol) in dioxane (40.0 mL), cool the system to 0 ° C, and slowly add hydrochloric acid-dioxane (4.00 M, 2.00 equivalents) to the system. After the addition, slowly warm the system to 25 ° C and stir at 25 ° C for 3 hours. Concentrate the reaction mixture in vacuo. Compound IM-3 is obtained as a white solid (3.00 g, crude product, hydrochloride).

[0115] Synthesis of key intermediate IM-4

[0116]

[0117] Step 1: Synthesis of IM-4a

[0118]

[0119] 4-(2-bromoacetyl)piperidine-1-carboxylic acid tert-butyl ester (15.0 g, 48.9 mmol, 1.00 eq) and 5-bromo-4-methoxypyridin-2-amine (9.95 g, 48.9 mmol, 1.00 eq) were dissolved in a mixed solution of toluene (100 mL) and acetonitrile (100 mL), and sodium bicarbonate (8.23 g, 97.9 mmol, 2.00 eq) was added to the system. After the addition, the resulting mixture was heated to 90 ° C and stirred for 12 hours. 200 mL of ice water was added to the reaction mixture at 0 ° C for quenching, and then extracted three times with 500 mL of ethyl acetate. The combined organic layer was washed with sodium chloride aqueous solution, dried with sodium sulfate, filtered and concentrated under reduced pressure to obtain an off-white solid compound IM-4a (15.0 g).

[0120] MS (ES+): m / z = 410.0 [M + H + ].

[0121] Step 2: Synthesis of IM-4b

[0122]

[0123] Compound IM-4a (5.00 g, 12.1 mmol, 1.00 eq) and 6-(trifluoromethyl)pyridine-2-carboxamide (6.95 g, 36.5 mmol, 3.00 eq) were dissolved in 1,4-dioxane (90.0 mL), and cesium carbonate (7.94 g, 24.3 mmol, 2.00 eq), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (xantphos) (2.82 g, 4.87 mmol, 0.40 eq) and palladium acetate (547 mg, 2.44 mmol, 0.20 eq) were added to the system in sequence. After the addition, the obtained mixture was heated to 100 ° C and stirred for 12 hours. 100 mL of water was added to the reaction mixture at 25 ° C for quenching, and then extracted three times with 100 mL of ethyl acetate. The combined organic layer was washed with sodium chloride aqueous solution, dried with sodium sulfate, filtered and concentrated under reduced pressure to obtain yellow solid compound IM-4b (3.90 g). MS (ES+): m / z = 520.2 [M+H + ].

[0124] Step 3: Synthesis of IM-4

[0125]

[0126] Compound IM-4b (4.00 g, 7.70 mmol, 1.00 eq) was dissolved in dioxane (40.0 mL), hydrochloric acid / 1,4-dioxane (4M, 40.0 mL) was slowly added dropwise to the system at 25° C., and the mixture was stirred at 25° C. for 12 hours. The mixture was concentrated in vacuo to obtain a crude compound IM-4 as a white solid (4.00 g, hydrochloride).

[0127] MS (ES+): m / z = 420.1 [M+H + ].

[0128] Synthesis of key intermediate IM-5

[0129]

[0130] Step 1: Synthesis of IM-5a

[0131]

[0132] 6-Fluoropyridine-2-carboxamide (10 g, 71.3 mmol, 1.00 eq) and morpholine (9.33 g, 107 mmol, 9.42 mL, 1.50 eq) were dissolved in N,N-dimethylformamide (100 mL), potassium carbonate (14.8 g, 107 mmol, 1.50 eq) was added to the system, and after the addition, the obtained mixture was heated to 100°C and stirred for 12 hours. The mixture was filtered and concentrated under reduced pressure to obtain a yellow solid compound IM-5a (10.0 g).

[0133] MS (ES+): m / z 208.1 [M+H + ].

[0134] Step 2: Synthesis of IM-5b

[0135]

[0136] Compound IM-3a (5.00 g, 12.1 mmol, 1.00 eq) and compound IM-5a (3.55 g, 17.1 mmol, 1.50 eq) were dissolved in 1,4-dioxane (50.0 mL), and cesium carbonate (7.43 g, 22.8 mmol, 2.00 eq), Xantphos (2.64 g, 4.56 mmol, 0.40 eq) and palladium acetate (512 mg, 2.28 mmol, 0.20 eq) were added to the system in sequence at 25 °C. After the addition, the obtained mixture was heated to 100 °C and stirred for 12 hours. The mixture was filtered and concentrated under reduced pressure to obtain a crude compound IM-5b as a yellow solid (5.00 g). MS (ES+): m / z 565.2 [M+H + ].

[0137] Step 3: Synthesis of IM-5c

[0138]

[0139] Compound IM-5b (2.00 g, 3.54 mmol, 1.00 eq) was dissolved in tetrahydrofuran (15.0 mL), and methylmagnesium bromide (3 M, 9.45 mL, 8.00 eq) was slowly added dropwise at 0 ° C. The mixture was then stirred at 25 ° C for 3 hours. 20.0 mL of aqueous ammonium chloride solution was added to the reaction mixture at 25 ° C for quenching, and then extracted with dichloromethane (15.0 mL * 3). The combined organic layer was washed with aqueous sodium chloride solution (5.00 mL * 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to obtain compound IM-5c as a yellow solid (500 mg). MS (ES +): m / z 565.2 [M + H+ ].

[0140] Step 4: Synthesis of IM-5

[0141]

[0142] Compound IM-5c (500 mg, 885 μmol, 1.00 eq) was dissolved in dichloromethane (1.00 mL), and trifluoroacetic acid (1.24 g, 10.6 mmol, 805 μL, 12 eq) was slowly added dropwise to the system at 25° C. The mixture was stirred at 25° C. for 4 hours and then concentrated in vacuo to obtain compound IM-5 as a white solid (500 mg, trifluoroacetate).

[0143] MS (ES+): m / z 465.3 [M+H + ].

[0144] Synthesis of key intermediate IM-6

[0145]

[0146] Step 1: Synthesis of IM-6a

[0147]

[0148] 6-Fluoropyridine-2-carboxamide (10.0 g, 71.2 mmol, 1.00 eq) and (1R, 4R)-2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride (14.5 g, 106 mmol, 1.50 eq) were dissolved in N,N-dimethylformamide (70.0 mL). Potassium carbonate (29.6 g, 214 mmol, 3.00 eq) was added to the reaction system at 25°C. After the addition, the resulting mixture was heated to 100°C and stirred for 12 hours. The reaction mixture was cooled to 25°C, poured into 100 mL of water for quenching, and then extracted with 300 mL (100 mL*3) of ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. Column chromatography (eluent, petroleum ether: ethyl acetate = 100: 1 to 0: 1) was used for separation and purification to obtain compound IM-6a as a white solid (13.0 g). LCMS: m / z 166.0 [M+H + ].

[0149] Step 2: Synthesis of IM-6b

[0150]

[0151] Compound IM-6a (6.00 g, 13.7 mmol, 1.00 eq) and compound IM-3a (4.50 g, 20.5 mmol, 1.50 eq) were dissolved in 1,4-dioxane (42.0 mL), and potassium carbonate (29.6 g, 214 mmol, 3.00 eq), palladium acetate (614 mg, 2.74 mmol, 0.20 eq), and Xantphos (3.17 g, 5.48 mmol, 0.40 eq) were added to the reaction system at 25 °C. After the addition, the nitrogen was replaced three times, and the resulting mixture was heated to 100 °C and stirred for 12 hours. The reaction mixture was cooled to 25 °C, poured into 100 mL of water to quench, and then extracted with ethyl acetate (100 mL*3). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The product was separated and purified by column chromatography (eluent, petroleum ether:ethyl acetate=100:1 to 0:1) to obtain compound IM-6b as a white solid (5.20 g).

[0152] LCMS: m / z 577.3 [M+H + ].

[0153] Step 3: Synthesis of IM-6c

[0154]

[0155] Compound IM-6b (4.00 g, 6.94 mmol, 1.00 eq) was dissolved in tetrahydrofuran (20.0 mL), and methylmagnesium bromide (3.00 M, 11.6 mL, 5.00 eq) was added to the reaction system at 0 ° C. After the addition, the resulting mixture was heated to 25 ° C and stirred for 1 hour. The reaction solution was slowly poured into 30.0 mL of saturated aqueous ammonium chloride solution in batches to quench, and then extracted with ethyl acetate (15.0 mL * 3). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. Column chromatography (eluent, petroleum ether: ethyl acetate = 100: 1 to 0: 1) was used for separation and purification to obtain compound IM-6c as a yellow oil (3.80 g). LCMS: m / z 577.3 [M+H + ].

[0156] Step 4: Synthesis of IM-6

[0157]

[0158] Compound IM-6c (2.00 g, 3.47 mmol, 1.00 eq) was dissolved in dichloromethane (20.0 mL), and trifluoroacetic acid (4.75 g, 41.2 mmol, 3.09 mL, 12.0 eq) was added to the reaction system at 0°C. After the addition, the resulting mixture was heated to 25°C and stirred for 2 hours. The reaction solution was concentrated under reduced pressure to obtain compound IM-6 as a brown oil (1.60 g, trifluoroacetate). LCMS: m / z 477.3 [M+H + ].

[0159] Key intermediate IM-7

[0160]

[0161] Step 1: Synthesis of IM-7a

[0162]

[0163] 1H-indazole-6-carboxylic acid methyl ester (50.0 g, 283 mmol, 1.00 eq) was dissolved in concentrated sulfuric acid (300 mL). Concentrated nitric acid (49.9 g, 554 mmol, 35.6 mL) was added dropwise at 0°C, and the reaction solution was stirred at 0°C for 3 hours. The reaction solution was slowly dripped into ice water (600 mL) to quench, filtered, and the filter cake was washed three times with sodium bicarbonate aqueous solution. The filter cake was dried to obtain compound IM-7a as a yellow solid (40.0 g). LCMS: m / z = 222.0 [M+H + ].

[0164] Step 2: Synthesis of IM-7b

[0165]

[0166] Compound IM-7a (5.00 g, 22.6 mmol, 1.00 eq) was dissolved in N, N-dimethylformamide (40.0 mL). Cesium carbonate (14.7 g, 45.2 mmol, 2.00 eq) and tert-butyl 4-(p-toluenesulfonyloxy)piperidine-1-carboxylate (8.04 g, 22.6 mmol, 1.00 eq) were added at room temperature, and then the reaction solution was stirred at 80 ° C for 12 hours. The three parallel crystal reaction solutions were combined and diluted with water (150 mL). The aqueous layer was extracted with ethyl acetate (80 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was chromatographed on a silica gel column to obtain IM-7b as a yellow solid compound (8.00 g). LCMS: m / z = 349.1 [M+H + ].

[0167] Step 3: Synthesis of IM-7c

[0168]

[0169] Compound IM-7b (8.00 g, 19.7 mmol, 1.00 eq) was dissolved in ethanol (40.0 mL) and water (20.0 mL), iron powder (5.52 g, 98.9 mmol, 5.00 eq) and calcium chloride (6.59 g, 59.3 mmol, 3.00 eq) were added at 25 °C, and the reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was diluted with water (40 mL) and extracted with ethyl acetate (40 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain IM-7c as a yellow solid (3.80 g). LCMS: m / z = 375.1 [M+H + ].

[0170] Step 4: Synthesis of IM-7d

[0171]

[0172] 6-Trifluoromethylpyridine-2-carboxylic acid (1.94 g, 10.1 mmol, 1.00 eq) was dissolved in tetrahydrofuran (20.0 mL), triethylamine (3.08 g, 30.4 mmol, 4.24 mL, 3.00 eq) and O-(7-azabenzotriazole-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphonate (5.79 g, 15.2 mmol, 1.50 eq) were slowly added, and then compound IM-7c (3.80 g, 10.1 mmol, 1.00 eq) was added. The reaction mixture was stirred at 25 ° C for 12 hours. The reaction mixture was diluted with water (20 mL), extracted with ethyl acetate (20.0 mL x 3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain compound IM-7d as a yellow oil (1.50 g). LCMS: m / z = 548.2 [M+H + ].

[0173] Step 5: Synthesis of IM-7e

[0174]

[0175] Compound IM-7d (1.6 g, 2.92 mmol, 1.00 eq) was dissolved in tetrahydrofuran (10.0 mL), methylmagnesium bromide (3 M, 4.87 mL, 5.00 eq) was added dropwise at 0 ° C, and the reaction mixture was stirred at 25 ° C for 2 hours. The reaction mixture was poured into saturated ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic phases were combined. Washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain IM-7e as a yellow solid (800 mg), which was used directly in the next step without purification. LCMS: m / z = 548.3 [M+H + ].

[0176] Step 6: Synthesis of IM-7

[0177]

[0178] Compound IM-7e (1.23 g, 2.25 mmol, 1.00 eq) was dissolved in dioxane (10.0 mL), and hydrochloric acid / dioxane (4 M, 12.30 mL, 21.9 eq) was added at 25°C. The reaction mixture was stirred for 2 hours and then concentrated under reduced pressure to obtain compound IM-7 as a yellow solid (600 mg, hydrochloride), which was used directly in the next step without purification. LCMS: m / z=448.2 [M+H + ]

[0179] Key intermediate IM-8

[0180]

[0181] Step 1: Synthesis of IM-8a

[0182]

[0183] 4-Hydroxybutan-2-one (5.00 g, 56.7 mmol, 1.00 eq) was dissolved in methanol (100 mL), and bromine (9.07 g, 56.7 mmol, 1.00 eq) was slowly added dropwise at 0 ° C. The mixture was stirred at 25 ° C for 2 hours, and hydrochloric acid (2M, 56.7 mL, 2.00 eq) was slowly added dropwise. After the addition, the resulting mixture was stirred at 25 ° C for 12 hours. The two parallel reactions were combined, 200 mL of water was added at 5 ° C to quench the reaction, and then extracted with dichloromethane (150 mL * 3). The combined organic layer was washed with sodium chloride aqueous solution (50 mL * 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to obtain compound IM-8a as a yellow oil (7.00 g).

[0184] Step 2: Synthesis of IM-8b

[0185]

[0186] Compound IM-8a (3.00 g, 17.9 mmol, 1.00 eq) was dissolved in a mixed solution of toluene (50.0 mL) and acetonitrile (50.0 mL), and 2-amino-5-bromopyridine-4-carboxylic acid methyl ester (4.15 g, 17.9 mmol, 1.00 eq) and sodium bicarbonate (3.02 g, 35.9 mmol, 2.00 eq) were added in sequence. The mixture was heated to 90 ° C and stirred at 90 ° C for 12 hours. The two parallel reactions were combined, filtered and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to obtain compound IM-8b as a yellow solid (2.50 g).

[0187] Step 3: Synthesis of IM-8c

[0188]

[0189] Dissolve compound IM-8b (2.00 g, 6.69 mmol, 1.00 eq) in N,N-dimethylformamide (20.0 mL) and slowly add imidazole (1.14 g, 16.7 mmol, 2.50 eq) at 0°C. Warm the mixture to 25°C and add tert-butyldiphenylsilyl chloride (2.76 g, 10.0 mmol, 1.50 eq). Warm the mixture to 40°C and stir for 12 hours. Concentrate the mixture under reduced pressure to obtain a crude compound IM-8c as a white solid (2.60 g).

[0190] Step 4: Synthesis of IM-8d

[0191]

[0192] 6-Trifluoromethylpyridine-2-carboxamide (707 mg, 3.72 mmol, 1.00 eq) was dissolved in 1,4-dioxane (100 mL), and cesium carbonate (3.64 g, 11.16 mmol, 3.00 eq), Xantphos Pd G4 (358 mg, 372 μmol, 0.10 eq) and compound IM-8c (2.00 g, 3.72 mmol, 1.00 eq) were added in sequence at 25 °C. The reaction mixture was heated to 100 °C and stirred at 100 °C for 12 hours. 100 mL of water was added at 5 °C to quench the reaction mixture, and then extracted with dichloromethane (150 mL*3). The organic layers were combined, washed with sodium chloride aqueous solution (50.0 mL*3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO 2 , petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to obtain a crude product of compound IM-8d as a yellow solid (2.00 g).

[0193] Step 5: Synthesis of IM-8e

[0194]

[0195] Compound IM-8d (1.30 g, 2.01 mmol, 1.00 eq) was dissolved in tetrahydrofuran (10.0 mL), methylmagnesium bromide (3 M, 3.35 mL, 5.00 eq) was slowly added dropwise at 0 ° C, and the reaction mixture was stirred at 25 ° C for 3 hours. 20.0 mL of water was added at 5 ° C to quench the reaction mixture, and then extracted with dichloromethane (15.0 mL * 3). The organic layers were combined, washed with sodium chloride aqueous solution (5.00 mL * 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to obtain compound IM-8e as a yellow solid (500 mg).

[0196] 1 H NMR: (400MHz, DMSO-d6) δ12.22(s,1H),9.54(s,1H),8.35-8.48(m,2H),8.16-8.21(m,1H), 7.78(s,1H),7.56-7.59(m,4H),7.38-7.44(m,7H),6.15(s,1H),3.94-3.99(m,2H),2.95(br t,J=6.9Hz,2H),1.59(s,6H),0.98(s,9H).

[0197] Step 6: Synthesis of IM-8

[0198]

[0199] Compound IM-8e (400 mg, 618 μmol, 1.00 eq) was dissolved in tetrahydrofuran (5.00 mL), and tetrabutylammonium fluoride (1 M, 3.09 mL, 5.00 eq) was added. The reaction mixture was stirred at 25 ° C for 2 hours and then concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to obtain compound IM-8 as a white solid (200 mg).

[0200] Embodiment 1:

[0201]

[0202] first step:

[0203]

[0204] Compound IM-3 (1.00 g, 2.23 mmol) and 2-bromo-1,1-diethoxyethane (880 mg, 4.47 mmol) were dissolved in acetone (2.00 mL), and potassium carbonate (926 mg, 6.70 mmol) and potassium iodide (185 mg, 1.12 mmol) were added in sequence. The resulting mixture was heated to 80 ° C and stirred for 12 hours. The mixture was concentrated to dryness under reduced pressure to obtain intermediate 1a as a yellow solid (300 mg).

[0205] Step 2:

[0206]

[0207] Compound 1a (300 mg, 532 μmol) was dissolved in water (3.00 mL), and hydrochloric acid / 1,4-dioxane (4 M, 3.00 mL) was slowly added dropwise to the system at 25° C. The mixture was stirred at 60° C. for 12 hours and then concentrated to dryness in vacuo to obtain intermediate 1b as a white solid (430 mg).

[0208] Step 3:

[0209]

[0210] Compound IM-1 (50.0 mg, 148 μmol, 1.00 eq) was dissolved in N, N-dimethylformamide (1.00 mL) and 1, 2-dichloroethane (1.00 mL). Triethylamine (45.2 mg, 446 μmol, 62.1 μL, 3.00 eq) was added to the reaction system at 25 °C, and the reaction was stirred at 25 °C for 30 minutes. Compound 1b (72.9 mg, 148 μmol, 1.00 eq), sodium triacetoxyborohydride (63.1 mg, 297 μmol, 2.00 eq) and glacial acetic acid (8.94 mg, 148 μmol, 8.53 μL, 1.00 eq) were then added to the reaction system. The reaction was stirred at 25 °C for 2.5 hours. 3.00 mL of water was added to the reaction mixture to quench, and then extracted with ethyl acetate (5 mL*3). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The product was purified by preliminary HPLC (formic acid conditions) to obtain compound 1 as a yellow solid (12.0 mg).

[0211] 1 H NMR: (400MHz, DMSO-d6) δ12.22(s,1H),11.12(s,1H),9.54(s,1H),8.43-8.48( m,1H),8.35-8.42(m,1H),8.15-8.22(m,2H),7.80(s,2H),7.41(s,1H),6.14(br s,1H),5.13(dd,J=5.4,12.9Hz,1H),4.02(s,4H),3.03(br d,J=11.1Hz,2H),2.83-2.92(m,3H),2.53-2.71(m,5H),2.17(br t,J=10.9Hz,2H),1.94-2.10(m,3H),1.66-1.78(m,2H),1.60(s,6H).

[0212] Embodiment 2:

[0213]

[0214] Compound IM2 (150 mg, 525 μmol, 1.00 eq) and compound 1b (257 mg, 525 μmol, 1.00 eq) were dissolved in N, N-dimethylformamide (1.00 mL) and tetrahydrofuran (1.00 mL). Anhydrous sodium acetate (129. mg, 1.58 mmol, 3.00 eq) was added to the reaction system at 25°C, and the reaction was stirred at 25°C for 30 minutes. Then sodium triacetoxyborohydride (334 mg, 1.58 mmol, 3.00 eq) and glacial acetic acid (31.5 mg, 525 μmol, 30.10 μL, 1.00 eq) were added to the reaction system. The reaction was stirred at 25°C for 11.5 hours. The reaction mixture was filtered and concentrated to obtain a crude product. It was purified by high performance liquid chromatography (formic acid system) to obtain compound 2 as a yellow solid (15.0 mg).

[0215] 1 H NMR: (400MHz, DMSO-d6) δ12.22(s,1H),10.97(brs,1H),9.54(s,1H),8.42-8.49(m,1H),8.34-8.42(m,1H),8. 19(d,J=7.6Hz,1H),7.79(s,1H),7.57(s,1H),7.43(d,J=15.0Hz,2H),6.14(s,1H),5.10(dd,J=5.1,13.3Hz,1H ),4.22-4.48(m,2H),3.94(brd,J=7.3Hz,4H),3.00(brd,J=10.9Hz,2H),2.85(brt,J=6.7Hz,3H),2.54-2.70( m,4H),2.32-2.41(m,1H),2.12(brt,J=10.8Hz,2H),1.92-2.05(m,3H),1.69(brd,J=10.4Hz,2H),1.60(s,6H).

[0216] LCMS: m / z = 759.3 [M+H + ].

[0217] Embodiment 3:

[0218]

[0219] first step:

[0220]

[0221] Compound IM-3 (1.00 g, 2.23 mmol, 1.00 eq) and 3-bromopropanal dimethyl acetal (449 mg, 2.46 mmol, 335 μL, 1.10 eq) were dissolved in N, N-dimethylformamide (10.0 mL), and potassium carbonate (926 mg, 6.70 mmol, 3.00 eq) and potassium iodide (185 mg, 1.12 mmol, 0.50 eq) were added to the system in sequence. After the addition, the resulting mixture was heated to 80 ° C and stirred for 12 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (20.0 ml) and extracted with ethyl acetate (3×20.0 ml). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Compound 3a was obtained as a yellow solid (200 mg).

[0222] 1 H NMR: (400MHz, CHLOROFORM-d6) δ12.25(s,1H),9.55(s,1H),8.43-8.51(m,2H),8.13(t,J=7.8Hz,1H),7.86(d,J=7.8Hz,1H),7.46(s,1H),7.33(s,1H ),4.82(brs,1H),3.30-3.38(m,8H),2.93(brt,J=10.8Hz,1H),2.77-2.87 (m,2H),2.58(brs,2H),2.16-2.28(m,2H),1.95-2.12(m,4H),1.72(s,6H).

[0223] LCMS: m / z 550.3 [M+H + ].

[0224] Step 2:

[0225]

[0226] Compound 3a (200 mg, 363 μmol, 1.00 eq) was dissolved in anhydrous formic acid (5.00 mL), and the mixture was stirred at 25° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain a crude compound 3b (200 mg), which was used directly in the next step without purification.

[0227] LCMS: m / z 504.2 [M+H + ].

[0228] Step 3:

[0229]

[0230] IM-1 (71.3 mg, 238 μmol, 1.20 eq) was dissolved in tetrahydrofuran (0.50 mL) and N,N-dimethylformamide (0.50 mL), sodium acetate (24.4 mg, 297 μmol, 1.50 eq) was added at 25° C., and then stirred at 25° C. for 0.5 hours. Sodium triacetoxyborohydride (126 mg, 595 μmol, 3.00 eq) and compound 3b (100 mg, 198 μmol, 1.00 eq) were added at 25° C., and then stirred at 25° C. for 12 hours. The reaction mixture was concentrated under reduced pressure to obtain the product, which was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [H2O(10mMNH4HCO3)-ACN]; gradient: 25%-60% B, time: 8.0 min) to obtain compound 3 as a white solid (12.0 mg). 1 H NMR: (400MHz, DMSO-d6) δ12.22(s,1H),11.11(s,1H),9.54(s,1H),8.44-8.47(m,1H),8.39(t,J=7.8Hz,1H),8.19(d,J=7.8Hz,1H) ,7.79(s,3H),7.41(s,1H),6.14(s,1H),5.13(dd,J=5.3,12.9Hz,1H),3.97(s,4H),2.81-3.01(m,4H),2.63-2.75(m,4H),2.39(br t,J=7.1Hz,2H),2.28-2.34(m,1H),2.04-2.08(m,2H),1.97(br d,J=11.0Hz,2H),1.70(br dd,J=8.9,12.3Hz,4H),1.60(s,6H).

[0231] LCMS: m / z = 787.3 [M+H + ].

[0232] Embodiment 4:

[0233]

[0234] Compound 3b (100 mg, 350 μmol, 1.00 eq) was dissolved in N,N-dimethylformamide (1.00 mL) and tetrahydrofuran (1.00 mL). Anhydrous sodium acetate (86.2 mg, 1.05 mmol, 3.00 eq) was added to the reaction system at 0°C, and the reaction was stirred at 0°C for 30 minutes. Then sodium triacetoxyborohydride (222 mg, 1.05 mmol, 3.00 eq), glacial acetic acid (42.1 mg, 701 μmol, 40.1 μL, 2.00 eq) and compound IM-2 (176 mg, 350 μmol, 1.00 eq) were added to the reaction system at 0°C, and the reaction was naturally heated to room temperature and stirred for 2 hours. The mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by high performance liquid chromatography (column: Phenomenex Gemini-NX 150*30mm*5um; mobile phase: [H2O(10mM NH4HCO3)-ACN]; gradient: 30%-55% B, time: 20.0min) to obtain compound 4 as a white solid (13.3mg).

[0235] 1 H NMR: (400MHz, DMSO-d6)δ12.22(s,1H),10.97(br s,1H),9.54(s,1H),8.34-8.49(m,2H),8.19(d,J=7.6Hz,1H),7.78(s,1H),7.56(s,1H),7. 43(d,J=14.1Hz,2H),6.15(s,1H),5.10(dd,J=5.1,13.2Hz,1H),4.22-4.46(m,2H),3.90(br d,J=5.5Hz,4H),2.85–3.00(m,3H),2.57-2.76(m,4H),2.32-2.45(m,3H),1.92-2.07(m,5H),1.64-1.77(m,4H),1.60(s,6H).

[0236] LCMS: m / z = 773.4 [M+H + ].

[0237] Embodiment 5:

[0238]

[0239] first step:

[0240]

[0241] Compound IM-4 (1.00 g, 2.38 mmol, 1.00 eq) and 2-bromo-1,1-diethoxyethane (939 mg, 4.77 mmol, 2.00 eq) were dissolved in acetone (10.0 mL), potassium carbonate (1.65 g, 11.9 mmol, 5.00 eq) and potassium iodide (197 mg, 1.19 mmol, 0.50 eq) were added to the system in sequence, and after the addition, the resulting mixture was heated to 80°C and stirred for 12 hours. The mixture was filtered and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (column: Phenomenex Gemini NX-C18 (75*30 mm*3 um); mobile phase: [H2O (0.05% NH3H2O ​​+ 10 mM NH4HCO3)-ACN]; gradient: 20%-50% B, time 8.0 min) to obtain compound 5a (340 mg) as a white solid. LCMS purity was 88.8%.

[0242] MS (ES+): m / z = 536.2 [M+H + ].

[0243] Step 2:

[0244]

[0245] Compound 5a (100 mg, 186 μmol, 1.00 eq) was dissolved in water (2.00 mL), hydrochloric acid / dioxane (4 M, 2.00 mL) was slowly added dropwise to the system at 25° C., and the mixture was stirred at 50° C. for 2 hours. The mixture was concentrated in vacuo to obtain compound 5b (100 mg) as a white solid.

[0246] Step 3:

[0247]

[0248] Compound IM-1 (64.8 mg, 216 μmol, 1.00 eq) was dissolved in 1,2-dichloroethane (1.00 mL) and N,N-dimethylformamide (1.00 mL), and N,N-diisopropylethylamine (84.0 mg, 650 μmol, 3.00 eq) was added at 25° C., and then stirred at 25° C. for 0.5 hours. Sodium triacetoxyborohydride (137 mg, 650 μmol, 3.00 eq), compound 5b (100 mg, 216 μmol, 1.00 eq) and acetic acid (19.5 mg, 325 μmol, 1.50 eq) were added at 0° C., and then stirred at 25° C. for 12 hours. The mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC (column: Phenomenex luna C18 100*40mm*5um; mobile phase: [H2O(0.2% FA)-ACN]; gradient: 1%-35% B, time: 8.0 min). The product was purified again by preparative HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [H2O(10mMNH4HCO3)-ACN]; gradient: 30%-65% B, time: 8.0 min) to obtain compound 5 as a white solid (7.00 mg).

[0249] 1 H NMR:(400MHz,DMSO-d6)δ11.11(br s,1H),10.19(s,1H),9.35(s,1H),8.39-8.47(m,2H),8.24(d,J=7.6Hz,1H),7.79(s,2H),7.65(s,1H),7.08(s,1H),5.13(dd,J=5.4,12.7Hz ,1H),3.95-4.06(m,7H),2.80-3.02(m,5H),2.53-2.64(m,4H),2.02- 2.16(m,3H),1.94-1.99(m,2H),1.59-1.75(m,2H),1.15-1.25(m,1H).

[0250] MS (ES+): m / z = 745.3 [M+H + ].

[0251] Embodiment 6:

[0252]

[0253] first step:

[0254]

[0255] Compound IM-2 (123 mg, 432 μmol, 1.00 eq) was dissolved in N, N-dimethylformamide (1.00 mL) and tetrahydrofuran (1.00 mL). Anhydrous sodium acetate (106 mg, 1.29 mmol, 3.00 eq) was added to the reaction system at 25 ° C. Then, glacial acetic acid (51.8 mg, 864 μmol, 49.4 μL, 2.00 eq), sodium triacetoxyborohydride (274 mg, 1.29 mmol, 3.00 eq) and compound 5b (200 mg, 432 μmol, 1.00 eq) were added to the reaction system. The reaction was stirred at 25 ° C for 12 hours. The mixture was filtered and concentrated in vacuo to obtain a residue. Purification by high performance liquid chromatography gave compound 6 (5.70 mg) as a white solid.

[0256] 1 HNMR:(400MHz,DMSO-d6)δ10.97(br d,J=3.1Hz,1H),10.19(s,1H),9.35(s,1H),8.34-8.51(m,2H),8.23(d,J=7.5Hz,1H),7.51-7.70(m,2H),7.45(s,1H),7.07(s,1H),5.09(br dd,J=5.1,13.4Hz,1H),4.38-4.56(m,1H),4.22-4.33(m,1H),3.98(s,3H),3.94(br d,J=6.9Hz,3H),3.00(br d,J=11.0Hz,2H),2.80-2.93(m,3H),2.55-2.68(m,3H),2.39(br dd,J=4.1,12.9Hz,1H),2.11(br t,J=10.9Hz,2H),1.93-2.02(m,3H),1.61-1.75(m,2H),1.23(br s,2H). LCMS:m / z=731.3[M+H + ].

[0257] Example 7

[0258]

[0259] first step:

[0260]

[0261] Compound IM-5 (500 mg, 864 μmol, 1.00 eq) and 2-bromo-1,1-diethoxyethane (187 mg, 950 μmol, 143 μL, 1.10 eq) were dissolved in N,N-dimethylformamide (10.0 mL). Diisopropylethylamine (335 mg, 2.59 mmol, 451 μL, 3.00 eq) was added to the system at 25 °C. After the addition, the resulting mixture was heated to 100 °C and stirred for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure. The resulting residue was purified by preparative high performance liquid chromatography (formic acid system) to obtain compound 7a as a white solid (170 mg).

[0262] MS (ES+): m / z 581.3 [M+H + ].

[0263] Step 2:

[0264]

[0265] Compound 7a (170 mg, 292 μmol, 1.00 eq) was slowly dripped into the system at 25°C with formic acid (4.22 mg, 86.1 μmol, 0.10 mL, 98.0% purity, 5.00 eq), and the reaction mixture was stirred at 60°C for 12 hours. The mixture was concentrated in vacuo to obtain compound 7b as a white solid (100 mg). MS (ES+): m / z 507.3 [M+H + ].

[0266] Step 3:

[0267]

[0268] Compound IM-2 (61.9 mg, 217 μmol, 1.10 eq) was dissolved in tetrahydrofuran (1.00 mL) and N,N-dimethylformamide (1.00 mL), sodium acetate (48.5 mg, 592 μmol, 3.00 eq) was added at 0°C, and then stirred at 0°C for 0.5 hours. Sodium triacetoxyborohydride (125 mg, 592 μmol, 3.00 eq), compound 7b (100 mg, 197 μmol, 1.00 eq) and acetic acid (48.58 mg, 592.19 μmol, 3.00 eq) were added at 0°C, and then stirred at 25°C for 3.5 hours. The mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC (column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [H2O(10mM NH4HCO3)-ACN]; gradient: 15%-55% B, time: 8.0min). The product was purified again by preparative HPLC (column: Phenomenex Gemini-NX 80*40mm*3um; mobile phase: [H2O(10mMNH4HCO3)-ACN]; gradient: 20%-60% B over 20.0min) to obtain compound 7 as a white solid (6.94mg).

[0269] 1 H NMR: (400MHz, DMSO-d6) δ11.98(s,1H),10.81-11.13(m,1H),9.56(s,1H),7.68-7.81(m,2H),7.57(s,1H),7. 42-7.49(m,2H),7.39(s,1H),7.10(d,J=8.5Hz,1H),5.98-6.26(m,1H),5.09(dd,J=4.9,13.3Hz,1H),4.41(br d,J=17.6Hz,1H),4.28(d,J=17.1Hz,1H),3.94(br d,J=7.1Hz,4H),3.72(br d,J=4.5Hz,4H),3.65(br d,J=4.8Hz,4H),3.00(br d,J=10.9Hz,3H),2.80-2.91(m,3H),2.65(br d,J=12.3Hz,2H),2.29-2.42(m,2H),2.12(br t,J=10.9Hz,2H),1.93-2.01(m,3H),1.65-1.71(m,2H),1.60(s,6H).

[0270] MS (ES+): m / z 776.3 [M+H + ].

[0271] Embodiment 8:

[0272]

[0273] first step:

[0274]

[0275] Compound IM-6 (1.00 g, 2.10 mmol, 1.00 eq) and 2-bromo-1,1-diethoxyethane (1.65 g, 8.39 mmol, 1.26 mL, 4.00 eq) were dissolved in N,N-dimethylformamide (10.0 mL). N,N-diisopropylethylamine (2.71 g, 20.9 mmol, 3.65 mL, 10.0 eq) was added to the reaction system at 25 °C. After the addition, the resulting mixture was heated to 100 °C and stirred for 12 hours. The reaction solution was poured into 10 mL of water to quench, and then extracted with ethyl acetate (10.0 mL*3). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. Column chromatography was used for separation and purification (eluent, petroleum ether: ethyl acetate = 100:1 to 0:1). Compound 8a was obtained as a yellow oil (500 mg).

[0276] LCMS: m / z 593.4 [M+H + ].

[0277] Step 2:

[0278]

[0279] Compound 8a (100 mg, 168.71 μmol, 1.00 eq) was added to formic acid (1.00 mL) at 25°C, and the reaction mixture was stirred at 60°C for 12 hours. The reaction mixture was concentrated under reduced pressure to obtain compound 8b as a yellow oil (170 mg, crude product), which was used directly in the next step without further purification.

[0280] LCMS: m / z 519.3 [M+H + ].

[0281] Step 3:

[0282]

[0283] Compound IM-2 (124 mg, 385 μmol, 1.00 eq, HCl) was dissolved in a mixed solution of tetrahydrofuran (2.00 mL) and N,N-dimethylformamide (2.00 mL). Sodium acetate (63.2 mg, 771 μmol, 2.00 eq) was added to the reaction system at 25°C. After the addition, the resulting mixture was stirred at 25°C for 0.5 hours. Sodium triacetoxyborohydride (245 mg, 1.16 mmol, 3.00 eq), glacial acetic acid (69.4 mg, 1.16 mmol, 66.2 μL, 3.00 eq) and compound 8b (200 mg, 385 μmol, 1.00 eq) were added, and the resulting mixture was stirred at 25°C for 11.5 hours. The reaction solution was poured into water (4.00 mL) for quenching, and then extracted with ethyl acetate (2.00 mL*3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The residue was concentrated under reduced pressure and separated by high performance liquid chromatography to obtain compound 8 as a white solid (8.60 mg).

[0284] 1 HNMR(400MHz,DMSO-d6)δ12.07(s,1H),10.60–11.32(m,1H),9.59(s,1H),7.71-7.76(m,2H),7.57(s,1H),7.45(s,1H),7.41-7.38(m,2H),6.76(br d,J=8.0Hz,1H),5.09(dd,J=5.1,13.0Hz,1H),4.70(s,1H),4.38-4.45(m,1H),4.21-4.37(m,1H),3.94(br d,J=6.9Hz,4H),3.82(d,J=7.4Hz,1H),3.69(d,J=7.4Hz,1H),3.55(br d,J=9.9Hz,1H),3.00(br d,J=11.1Hz,2H),2.88-2.95(m,1H),2.85(br t,J=6.9Hz,2H),2.56-2.69(m,6H),2.32-2.41(m,2H),2.12(br t,J=10.6Hz,2H),1.88-1.99(m,5H),1.66-1.73(m,2H),1.64(s,3H),1.58(s,3H). LCMS m / z 788.4[M+H + ].

[0285] Embodiment 9:

[0286]

[0287] first step:

[0288]

[0289] Compound 9a (20.0 g, 88.6 mmol, 1.00 eq) was dissolved in acetonitrile (100 mL) and morpholine (11.5 g, 132 mmol, 11.7 mL, 1.50 eq) was added at room temperature, and finally N,N-diisopropylethylamine (22.9 g, 177 mmol, 30.8 mL, 2.00 eq) was added, and the reaction solution was stirred at 60°C for 12 hours. The reaction solution was concentrated under reduced pressure to a solid and purified by beating with methyl tert-butyl ether (80.0 mL) to obtain compound 9b as a white solid (15.0 g).

[0290] LCMS: m / z = 277.1 [M+H + ].

[0291] Step 2:

[0292]

[0293] Compound 9b (15.0 g, 54.2 mmol, 1.00 eq) was dissolved in methanol (75.0 mL) and water (15.0 mL), and lithium hydroxide (6.50 g, 271 mmol, 5.00 eq) was slowly added at room temperature, and the reaction was stirred at 60°C for 12 hours. The reaction solution was adjusted to pH 3-4 with 1.00 M hydrochloric acid, and the methanol was concentrated under reduced pressure. The filter cake was filtered and washed with water (30.0 mL), and vacuum dried to obtain 9c as a white compound (8.00 g).

[0294] LCMS: m / z = 249.1 [M+H + ].

[0295] Step 3:

[0296]

[0297] Ammonium chloride (5.17 g, 96.6 mmol, 3.00 eq) was dissolved in N, N-dimethylformamide (80.0 mL), and N, N-diisopropylethylamine (12.5 g, 96.6 mmol, 16.8 mL, 3.00 eq) was added at 25 ° C, and then O-(7-azabenzotriazole-1-YL)-N, N, N, N-tetramethyluronium hexafluorophosphonate (HATU, 18.3 g, 48.3 mmol, 1.50 eq) and compound 9c (8.00 g, 32.2 mmol, 1.00 eq) were added, and the reaction solution was stirred at 25 ° C for 12 hours. Water (40.0 mL) was added to dilute the reaction mixture and extracted with ethyl acetate (40 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was chromatographed on a silica gel column to give 9d (3.80 g) as a yellow solid.

[0298] 1 H NMR: (400MHz, DMSO-d6) δ 8.76 (d, J = 7.9 Hz, 1H), 8.16 (s, 1H), 7.11-7.27 (m, 2H), 6.84 (d, J = 7.9 Hz, 1H), 3.71 (s, 8H).

[0299] LCMS: m / z = 248.1 [M+H + ].

[0300] Step 4:

[0301]

[0302] Compound 3a (3.00 g, 6.84 mmol, 1.00 eq) and compound 9d (1.86 g, 7.53 mmol, 1.10 eq) were dissolved in 1,4-dioxane (30.0 mL), and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (850 mg, 1.47 mmol, 0.40 eq), cesium carbonate (2.40 g, 7.35 mmol, 2.00 eq) and palladium acetate (165 mg, 735 μmol, 0.20 eq) were added under nitrogen protection at 25°C. The reaction solution was stirred at 100°C for 12 hours. The reaction mixture was cooled to room temperature, poured into water (30.0 mL), extracted with ethyl acetate (50.0 mL x 3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column to obtain 9e as a yellow solid (1.20 g). LCMS: m / z = 605.3 [M+H + ].

[0303] Step 5:

[0304]

[0305] Compound 9e (1.70 g, 2.81 mmol, 1.00 eq) was dissolved in tetrahydrofuran (20.0 mL), and methylmagnesium bromide (4.00 M, 6.00 mL, 8.54 eq) was added dropwise at 0°C, and the reaction solution was stirred at 25°C for 3 hours. The reaction mixture was diluted with ammonium chloride (20.0 mL) and extracted with ethyl acetate (40 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by high performance liquid chromatography to obtain compound 9f (300 mg) as a white solid.

[0306] 1 H NMR: (400MHz, DMSO-d6) δ9.95(s,1H),8.67(s,1H),8.20(s,1H),7.67(d, J=16.0Hz,2H),7.37(s,1H),4.25-4.36(m,1H),3.84–4.03(m,2H),3.76-3 .90(m,2H),3.57-3.69(m,6H),3.14-3.26(m,1H),2.91-2.97(m,1H),2.79 -2.91(m,3H),2.65-2.75(m,1H),1.91-1.99(m,2H),1.60(s,1H),1.50(br d,J=5.9Hz,6H),1.41(s,9H).

[0307] LCMS: m / z = 605.3 [M+H + ].

[0308] Step 6:

[0309]

[0310] Compound 9f (300 mg, 496 μmol, 1.00 eq) was dissolved in dichloromethane (3.00 mL), trifluoroacetic acid (565 mg, 4.96 mmol, 368 μL, 10.0 eq) was slowly added at room temperature, and the reaction solution was stirred at 25°C for 12 hours. The reaction solution was concentrated to obtain compound 9g as a yellow solid (300 mg, trifluoroacetate), which was used directly in the next step without further purification.

[0311] LCMS: m / z = 505.2 [M+H + ].

[0312] Step 7:

[0313]

[0314] Compound 9g (300 mg, 594 μmol, 1.00 eq) was dissolved in N,N-dimethylformamide, potassium carbonate (410 mg, 2.97 mmol, 5.00 eq), bromoacetaldehyde diethyl acetal (140 mg, 713 μmol, 107 μL, 1.20 eq) and potassium iodide (49.3 mg, 297 μmol, 0.5 eq) were added, and the reaction mixture was stirred at 100°C for 12 hours. The reaction mixture was concentrated under reduced pressure to a solid, and purified by high performance liquid chromatography to obtain compound 9h as a yellow solid (60.0 mg, crude product). LCMS: m / z = 621.3 [M+H + ].

[0315] Step 8:

[0316]

[0317] Compound 9h (60.0 mg, 96.6 μmol, 1.00 eq) was dissolved in water (1.00 mL) and hydrochloric acid (1.00 mL), and the reaction solution was stirred at 50°C for 12 hours. The reaction mixture was concentrated to give compound 9i as a yellow solid (40.0 mg), which was used directly in the next step without further purification. LCMS: m / z = 547.4 [M+H + ].

[0318] Step 9:

[0319]

[0320] Compound IM-2 (26.1 mg, 91.4 μmol, 1.00 eq) was dissolved in N, N-dimethylformamide (1.00 mL) and tetrahydrofuran (1.00 mL), and sodium acetate (15.0 mg, 182 μmol, 2.00 eq) was added at room temperature, followed by acetic acid (16.4 mg, 274 μmol, 15.7 μL, 3.00 eq), sodium acetate borohydride (58.1 mg, 274 μmol, 3.00 eq) and compound 9i (50.0 mg, 91.4 μmol, 1.00 eq), and the reaction solution was stirred at 25° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to a solid, and purified by high performance liquid chromatography to obtain compound 9 as a white solid (10.0 mg).

[0321] 1H NMR: (400MHz, DMSO-d6) δ10.22(s,1H),8.68-8.89(m,2H),8.29(s,1H),7.60-7.71(m,1H),7.37(s,1H),6.87(d,J=7.9Hz,1H),3.94(br d,J=8.8Hz,3H),3.78(br s,5H),3.69(br d,J=4.3Hz,4H),2.94–3.05(m,3H),2.77-2.87(m,3H),1.89–2.19(m,8H),1.61-1.76(m,3H),1.51(s,6H).

[0322] LCMS: m / z = 816.3 [M+H + ].

[0323] Example 10

[0324]

[0325] first step:

[0326]

[0327] Compound 10a (23.0 g, 101 mmol, 1.00 eq) and morpholine (13.3 g, 152 mmol, 13.4 mL, 1.50 eq) were dissolved in N, N-dimethylformamide (115 mL), potassium carbonate (42.2 g, 305 mmol, 3.00 eq) was added to the reaction system at 25 ° C. After addition, the resulting mixture was heated to 100 ° C and stirred for 12 hours. The reaction mixture was cooled to 25 ° C, and the reaction solution was poured into 100 mL of water for quenching, and then extracted with dichloromethane (100 mL * 2). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. Column chromatography was used for separation and purification (eluent, petroleum ether: ethyl acetate = 100: 1 to 0: 1). Compound 10b (18.0 g) was obtained as a yellow solid.

[0328] LCMS: m / z 277.1 [M+H + ].

[0329] Step 2:

[0330]

[0331] Compound 10b (16.0 g, 57.9 mmol, 1.00 eq) was dissolved in methanol (90.0 mL) and water (18.0 mL), and lithium hydroxide monohydrate (4.86 g, 115 mmol, 2.00 eq) was added to the reaction system at 25°C. After the addition, the resulting mixture was heated to 60°C and stirred for 3 hours. The reaction mixture was cooled to 25°C, and the pH value of the reaction solution was adjusted to 4 with 1.00 M hydrochloric acid, and a white solid was precipitated, which was filtered and concentrated under reduced pressure to obtain compound 10c as a white solid (12.0 g).

[0332] LCMS: m / z 249.0 [M+H + ].

[0333] Step 3:

[0334]

[0335] Compound 10c (10.0 g, 40.2 mmol, 1.00 eq) was dissolved in N,N-dimethylformamide (50.0 mL). N,N-diisopropylethylamine (15.6 g, 120 mmol, 21.0 mL, 3.00 eq), O-(7-azabenzotriazole-1-YL)-N,N,N,N-tetramethyluronium hexafluorophosphonate (22.9 g, 60.4 mmol, 1.50 eq) and ammonium chloride (6.46 g, 120 mmol, 3.00 eq) were added to the reaction system at 25°C. The resulting mixture was stirred at 25°C for 12 hours. The reaction mixture was cooled to 25°C and the reaction solution was poured into 100 mL of water to quench, and then extracted with ethyl acetate (100 mL*3). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The product was separated and purified by column chromatography (eluent: petroleum ether:ethyl acetate = 100 / 1 to 0 / 1) to obtain compound 10d as a white solid (5.20 g).

[0336] 1HNMR: (400MHz, DMSO-d6) δ7.99–8.09(m,2H),7.80-7.99(m,2H),7.37(d,J=10.0Hz,1H),3.73-3.79(m,4H),3.47-3.52(m,4H).

[0337] Step 4:

[0338]

[0339] Compound 10d (3.20 g, 12.9 mmol, 1.00 eq) and compound IM-3a (5.38 g, 12.3 mmol, 0.95 eq) were dissolved in 1,4-dioxane (20.0 mL). Palladium acetate (581 mg, 2.59 mmol, 0.20 eq), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (3.00 g, 5.18 mmol, 0.40 eq) and cesium carbonate (12.7 g, 38.8 mmol, 3.00 eq) were added to the reaction system at 25 °C. After the addition, the resulting mixture was heated to 100 °C and stirred for 12 hours. The reaction mixture was poured into 20.0 mL of aqueous solution to quench, and then extracted with ethyl acetate (15.0 mL*3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was separated and purified by column chromatography (eluent, petroleum ether:ethyl acetate=100 / 1 to 0 / 1) to obtain compound 10e as a white solid (4.00 g).

[0340] 1 HNMR: (400MHz, DMSO-d6) δ11.13(s,1H),9.27-9.32(m,1H),8.13-8.19(m,2H),8.09(d,J=10.0Hz,1H),8. 00-8.04(m,1H),7.43(d,J=10.0Hz,1H),3.84(s,3H),3.72-3.76(m,4H),3.58-3.62(m,4H),1.41(s,9H).

[0341] Step 5:

[0342]

[0343] Compound 10e (4.00 g, 6.62 mmol, 1.00 eq) was dissolved in tetrahydrofuran (20.0 mL), and methylmagnesium bromide (3.00 M, 28.6 mL, 13.0 eq) was added to the reaction system at 0°C. After the addition, the resulting mixture was heated to 25°C and stirred for 3 hours. The reaction mixture was poured into a saturated aqueous ammonium chloride solution (20.0 mL) for quenching, and then extracted with ethyl acetate (20.0 mL*3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. After concentration under reduced pressure, the mixture was separated by high performance liquid chromatography to obtain compound 10f as a yellow solid (2.00 g).

[0344] Step 6:

[0345]

[0346] Compound 10f (1.20 g, 1.98 mmol, 1.00 eq) was added to dichloromethane (10.0 mL), trifluoroacetic acid (3.39 g, 29.7 mmol, 2.21 mL, 15.0 eq) was added to the reaction system at 25°C, and the mixture was stirred at 25°C for 4 hours. The reaction mixture was concentrated under reduced pressure to obtain compound 10g as a brown oil (1.05 g, crude product), which was used directly in the next step without further purification.

[0347] Step 7:

[0348]

[0349] Compound 10g (1.00g, 1.98mmol, 1.00eq) and bromoacetaldehyde diethyl acetal (1.56g, 7.93mmol, 4.00eq) were dissolved in N,N-dimethylformamide (10.0mL). Potassium iodide (164mg, 990μmol, 0.50eq) was added to the reaction system at 25°C. After potassium carbonate (821mg, 5.95mmol, 3.00eq) was added, the resulting mixture was heated to 100°C and stirred for 4 hours. The reaction mixture was cooled to 25°C and poured into 10mL of water to quench, and then extracted with ethyl acetate (5mL*3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 10h as a white solid (700mg). Step 8:

[0350]

[0351] At 25°C, compound 10h (1.20 g, 1.98 mmol, 1.00 eq) was added to hydrochloric acid (6 M, 5.00 mL, 37.2 eq), the mixture was heated to 50°C, and stirred at 50°C for 4 hours. The pH value of the reaction solution was adjusted to 7 with a saturated sodium bicarbonate aqueous solution. The reaction solution after adjustment was lyophilized. Compound 10i was obtained as a brown solid (200 mg, crude product).

[0352] Step 9:

[0353]

[0354] Compound IM-2 (104 mg, 365 μmol, 1.00 eq) was dissolved in a mixed solution of tetrahydrofuran (2.00 mL) and N,N-dimethylformamide (2.00 mL). Sodium acetate (60.0 mg, 731 μmol, 2.00 eq) was added to the reaction system at 25°C. After the addition, the resulting mixture was stirred at 25°C for 30 minutes. Sodium triacetoxyborohydride (232 mg, 1.10 mmol, 3.00 eq), glacial acetic acid (65.92 mg, 1.10 mmol, 62.8 μL, 3.00 eq) and compound 10i (200 mg, 365 μmol, 1.00 eq) were then added, and the resulting mixture was stirred at 25°C for 11.5 hours. The reaction mixture was poured into water (2 mL) for quenching, and then extracted with ethyl acetate (2 mL*3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated by HPLC to give Compound 10 (13.0 mg) as a yellow solid.

[0355] 1 HNMR:(400MHz,DMSO-d6)δ10.71(br s,1H),8.77(s,1H),8.12(s,1H),8.08(d,J=10.1Hz,1H),7.69(s,1H),7.57(s,1H),7.45(s,1H),7 .41(t,J=5.1Hz,2H),5.10(dd,J=5.1,13.2Hz,1H),4.36-4.46(m,1H),4.21-4.34(m,1H),3.94(br d,J=7.4Hz,4H),3.69-3.73(m,4H),3.52-3.56(m,4H),2.78–3.07(m,6H),2.57-2.74(m,3H),2.31-2.46(m,2H),2.13(br t,J=10.4Hz,2H),1.87–2.06(m,4H),1.64-1.73(m,2H),1.50(s,6H).

[0356] LCMS: m / z 816.5 [M+H + ].

[0357] Embodiment 11:

[0358]

[0359] first step:

[0360]

[0361] Compound IM-8 (200 mg, 489 μmol, 1 eq) was dissolved in tetrahydrofuran (5.00 mL), and triethylamine (123 mg, 1.22 mmol, 170 μL, 2.50 eq) and methanesulfonic anhydride (127 mg, 734 μmol, 1.50 eq) were added in sequence. The reaction mixture was stirred at 25 ° C for 12 hours. 2.00 mL of water was added to the reaction mixture at 0 ° C for quenching, and then extracted with dichloromethane (5 mL * 3), the organic layer was washed with sodium chloride aqueous solution (5 mL * 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain 11a as a white solid compound (200 mg).

[0362] Step 2:

[0363]

[0364] Compound 11a (120 mg, 246 μmol, 1.00 eq) was dissolved in N, N-dimethylformamide (5.00 mL), and piperidin-4-one hydrochloride (36.7 mg, 271 μmol, 1.10 eq), sodium iodide (73.9 mg, 493 μmol, 2.00 eq) and potassium carbonate (102 mg, 740 μmol, 3.00 eq) were added in sequence, and the mixture was heated to 80°C and stirred for 12 hours. The reaction mixture was concentrated under reduced pressure to obtain yellow solid compound 11b (30 mg).

[0365] Step 3:

[0366]

[0367] Compound IM-1 (21.4 mg, 71.5 μmol, 1.00 eq) and N,N-diisopropylethylamine (36.9 mg, 286 μmol, 4.00 eq) were dissolved in 1,2-dichloroethane (1.00 mL) and N,N-dimethylformamide (1.00 mL), and stirred at 25° C. for 0.5 hours. Sodium triacetoxyborohydride (45.4 mg, 214 μmol, 3.00 eq), compound 11b (35.0 mg, 71.5 μmol, 1.00 eq) and acetic acid (4.29 mg, 71.5 μmol, 1.00 eq) were added in sequence, and then stirred at 25° C. for 12 hours. The reaction mixture was concentrated under reduced pressure to give the product, which was purified by preparative HPLC (column: Phenomenex luna C18 100*40mm*5um; mobile phase: [H2O(0.2% FA)-ACN]; gradient: 1%-40% B over 8.0 min]; gradient: 20%-65% B, time: 8.0 min) to give compound 11 as a white solid (7.00 mg).

[0368] 1 H NMR: (400MHz, DMSO-d6) δ12.21(s,1H),11.11(s,1H),9.54(s,1H),8.43-8.46(m,1H),8.39(t,J=7.8Hz,1H),8.11-8.24(m,2H),7.73-7.83(m ,3H),7.40(s,1H),6.14(s,1H),5.13(dd,J=5.3,12.9Hz,1H),4.01(s,4H),2.82-2.99(m,5H),2.53-2.71(m,4H),2.00-2.17(m,3H),1.90(br d, J=9.3Hz, 2H), 1.60 (s, 6H), 1.50 (q, J=10.3Hz, 2H).

[0369] Embodiment 12:

[0370]

[0371] first step:

[0372]

[0373] Compound IM-7 (500 mg, 1.12 mmol, 1.00 eq) and bromoacetaldehyde diethyl acetal (440 mg, 2.23 mmol, 336 μL, 2.00 eq) were dissolved in N, N-dimethylformamide (5.00 mL), and N, N-diisopropylethylamine (144 mg, 1.12 mmol, 194 μL, 1.00 eq) was added at 25 ° C. The reaction solution was heated to 100 ° C and stirred for 12 hours. The reaction mixture was added to ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was purified by high performance liquid chromatography to obtain compound 12a as a yellow solid (150 mg) LCMS: m / z = 564.2 [M+H + ].

[0374] Step 2:

[0375]

[0376] Compound 12a (50.0 mg, 88.7 μmol, 1.00 eq) was dissolved in dioxane (1.00 mL) and water (1.00 mL), and hydrochloric acid / dioxane (4 M, 1.00 mL, 45.0 eq) was slowly added at room temperature, and the reaction solution was stirred at 50°C for 1 h. The reaction mixture was concentrated to obtain compound 12b as a yellow solid (40.0 mg), which was used directly in the next step without further purification.

[0377] LCMS: m / z=508.1 [M+18].

[0378] Step 3:

[0379]

[0380] Compound IM-2 (29.0 mg, 102 μmol, 1.00 eq) was dissolved in N, N-dimethylformamide (1.00 mL) and tetrahydrofuran (1.00 mL), sodium acetate (25. mg, 306 μmol, 3.00 eq) was added at 0°C, and the reaction was stirred at 0°C for 30 minutes, sodium acetate borohydride (43.3 mg, 204 μmol, 2.00 eq), glacial acetic acid (18.4 mg, 306 μmol, 17 μL, 3.00 eq) and compound 12b (50.0 mg, 102 μmol, 1.00 eq) were added at 0°C, and the reaction was stirred at 25°C for 1.5 hours. The reaction solution was concentrated under reduced pressure to a solid, and the crude product was purified by high performance liquid chromatography to obtain compound 12 as a white solid (11.4 mg).

[0381] 1 H NMR(400MHz,DMSO-d6)δ12.37(s,1H),10.97(br s,1H),8.72(s,1H),8.31-8.48(m,3H),8.16(d,J=7.8Hz,1H),7.58(d,J=2 .4Hz,2H),7.46(s,1H),5.95(s,1H),5.10(dd,J=5.1,13.3Hz,1H),4.42(br d,J=17.4Hz,2H),4.23-4.33(m,1H),3.96(br d,J=7.0Hz,4H),3.09(br d,J=10.5Hz,2H),2.87(br t,J=6.7Hz,3H),2.56-2.65(m,3H),2.39(brdd,J=4.6,13.1Hz,1H),2.18-2.27(m,2H),2.06-2.17(m,4H),1.96-2.04(m,1H),1.62(s,6H).

[0382] LCMS: m / z = 759.3 [M+H + ].

[0383] Embodiment 13:

[0384]

[0385] Compound IM-7 (200 mg, 446 μmol, 1.00 eq) was dissolved in N, N-dimethylformamide (2.00 mL) and dichloroethane (2.00 mL). N, N-diisopropylethylamine (115 mg, 893 μmol, 155 μL, 2.00 eq) was added, followed by compound 13a (152 mg, 446 μmol, 1.00 eq), sodium triacetoxyborohydride (284 mg, 1.34 mmol, 3.00 eq) and acetic acid (80.5 mg, 1.34 mmol, 76.7 μL, 3.00 eq). The reaction solution was stirred at 25 ° C for 12 hours. The mixture was filtered and concentrated under reduced pressure. The residue was purified by high performance liquid chromatography (ammonium bicarbonate system) to obtain compound 13 as a yellow solid (5.00 mg).

[0386] 1 HNMR(400MHz,DMSO-d6)δ12.37(s,1H),10.98–11.23(m,1H),8.72(s,1H),8.31-8.53(m,3H),8.16(d,J=7.6 Hz,1H),7.80(s,2H),7.58(s,1H),5.94(s,1H),5.05-5.24(m,1H),4.37-4.54(m,1H),4.03(s,4H),3.09(br d,J=10.5Hz,2H),2.83-2.95(m,3H),2.53-2.60(m,3H),2.02-2.31(m,8H),1.62(s,6H).

[0387] The compound prepared in the example was subjected to an IRAK4 protein degradation experiment, and the experimental process was as follows:

[0388] HiBiT-based THP1-HIBiT-IRAK4 intracellular degradation experiment

[0389] THP1-HIBiT-IRAK4 cells (wild-type cells purchased from ATCC, HIBiT tag inserted into the C-terminus of IRAK4 by CRISPR-Cas9 technology) were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS) (37°C, 5% CO2).

[0390] a) THP1-HIBiT-IRAK4 cells were seeded in a 384-well plate at 5000 cells / 40 μL / well.

[0391] b) The compound was diluted with DMSO to a stock solution of 10 mM, 3.33 mM, 1.11 mM, 0.37 mM, 0.12 mM, 0.04 mM, 0.013 mM, 0.005 mM, 0.002 mM, and 0 mM for later use.

[0392] c) The diluted compounds were added into the wells at 40 nL / well and incubated at 37°C and 5% CO2 for 24 h.

[0393] d) Add HiBiT cleavage detection reagent to the wells, incubate the plate at room temperature for 30 min, and then read the luminescence value on Envision.

[0394] Degradation rate (%) = (luminescence value of compound well / average luminescence value of DMSO well) × 100

[0395] XLFIT software was used to obtain the DC of the compound using the following nonlinear fitting formula: 50 (half degradation concentration):

[0396] Y=Bottom+(Top-bottom) / (1+10^((LogDC 50 -X)*HillSlope))

[0397] X: log value of compound concentration;

[0398] Y: Degradation rate

[0399] Bottom: Baseline value

[0400] Top: Maximum response value

[0401] HillSlope: The slope of the curve fitted by XLFIT software.

[0402] IRAK4 protein degradation in DCs 50 The results are shown in Table 1. The experimental results show that the compounds of Examples 1-8 and Examples 11-13 have significant degradation activity on IRAK4 protein, while the compounds of Examples 9 and 10 have no IRAK4 protein degradation activity (DC 50 >10000nM).

[0403] Table 1

[0404]

[0405]

[0406]

[0407] Assay of IRAK4 degradation by Western blotting

[0408] (1) Compound treatment and lysate preparation

[0409] a) On day 1, OCI-LY10 cells (purchased from Nanjing Kebai Biotechnology Co., Ltd., Kebai CBP60558) were cultured at 1.5×10 6 The cells / mL / well were inoculated into a 12-well plate, and then the test compound was diluted with DMSO, and 1uL of the diluted compound solution was added to the cell supernatant, and incubated in a 37°C, 5% CO2 incubator overnight.

[0410] b) On day 2, cells were harvested and transferred to 1.5 mL centrifuge tubes and centrifuged at 3000 rpm for 5 minutes.

[0411] c) Wash cells once with ice-cold PBS and centrifuge at 3000 rpm for 5 minutes at 4°C.

[0412] d) Add one tablet of protease inhibitor and one tablet of phosphatase inhibitor to 20 mL of cell lysis buffer and mix gently until completely dissolved. Take the prepared cell lysis buffer, add 50 ul / tube to a centrifuge tube, and lyse the cells on ice for 30 minutes.

[0413] e) Centrifuge at 13,000 rpm for 15 minutes at 4°C.

[0414] f) Transfer the supernatant to a new tube and determine the protein concentration by BCA kit.

[0415] (2) Western blotting

[0416] a) Add 20 ug / well of the sample to a 4-12% BTMidi protein gel (1 mm, 26 wells), and run electrophoresis at a constant voltage of 120 V for 5 minutes and at a constant voltage of 150 V for 55 minutes.

[0417] b) The samples were transferred to PVDF membrane using a Bio-Rad wet transfer apparatus at 300 mA for 90 minutes.

[0418] c) Block the membrane with 1xTBS-T containing 5% BSA for 1 hour at room temperature.

[0419] d) The membrane was incubated with the corresponding primary antibody solution (rabbit anti-IRAK4 and mouse anti-GAPDH) at 4°C overnight.

[0420] e) The membrane was washed 3×7 minutes with 1×TBST, and incubated with secondary antibody solution (HRP-labeled anti-mouse antibody and HRP-labeled anti-rabbit antibody) at room temperature for 60 minutes.

[0421] f) Wash the membrane 3 x 7 min with 1 x TBST.

[0422] g) Enhanced chemiluminescence (ECL) substrate was added and scanned by IBrightCL1500 imaging system.

[0423] The experimental results are as follows Figure 1-Figure 13 As shown in Table 2, Figure 1-Figure 13 Corresponding to the compounds, the results showed that all the compounds in the examples had significant IRAK4 protein degradation activity at concentrations of 100 nM and 1000 nM.

[0424] Table 2

[0425]

[0426]

[0427]

[0428] The applicant declares that the present invention illustrates the compounds of the present invention and their preparation and application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials selected by the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A tricyclic compound, its stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts, characterized in that: The tricyclic compound has a structure as shown in the following formula I: in: It is expressed as a single bond or a double bond, provided that the valence requirements are met; A is a 6-10 membered aryl group or a 5-10 membered heteroaryl group; B is a substituted or unsubstituted C2-C4 alkyl group, a substituted or unsubstituted 4-10 membered cycloalkyl group, or a substituted or unsubstituted 4-10 membered heterocycloalkyl group; C is a substituted or unsubstituted C2-C4 alkyl, a substituted or unsubstituted 4-10 membered cycloalkyl, or a substituted or unsubstituted 4-10 membered heterocycloalkyl; One of X and Y is a nitrogen atom and the other is a carbon atom; Z is CH2 or C=O; R a Each is independently selected from hydrogen, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, di(C1-C4 alkyl)amino, 5-10 membered cycloalkyl, 5-10 membered heterocycloalkyl; m is an integer from 0 to 5; R b Selected from C1-C4 alkoxy, C3-C6 cycloalkyloxy or , R1 and R2 are each independently selected from C1-C4 alkyl groups, and the wavy line represents the attachment site of the group.

2. The tricyclic compound according to claim 1, its stereoisomers, geometric isomers, tautomers or pharmaceutically acceptable salts, characterized in that: The substituents in the substituted groups are selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl or -O-(C1-C6 alkyl); Preferably, the ring A is The wavy line represents the attachment site of the group.

3. The tricyclic compound according to any one of claims 1 or 2, its stereoisomers, geometric isomers, tautomers or pharmaceutically acceptable salts, characterized in that: The structure of B is Or -CH2CH2-, the wavy line represents the attachment site of the group.

4. The tricyclic compound, stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, characterized in that: The C structure is -CH2-, -CH2CH2- or -CH2CH2CH2-, the wavy line represents the attachment site of the group.

5. The tricyclic compound, stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that: R a are each independently selected from hydrogen, fluorine, chlorine, cyano, trifluoromethyl, trifluoromethoxy, The wavy lines represent the attachment sites of the groups; Preferably, Selected from The wavy lines represent the attachment sites of the groups; Preferably, R b is selected from methoxy, ethoxy, isopropoxy, cyclopropyloxy or In any of the above, the wavy line represents the attachment site of the group.

6. The tricyclic compound, stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that: The tricyclic compound is selected from any one of the compounds with the following structures:

7. The tricyclic compound, stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, characterized in that: The pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, hydrochlorides, hydrobromides, hydroiodides, acetates, propionates, caprates, octanoates, acrylates, formates, isobutyrates, hexanoates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1 any of the following salts: benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate or mandelate.

8. A tricyclic IRAK4 degrader, comprising the tricyclic compound according to any one of claims 1 to 7, its stereoisomers, geometric isomers, tautomers or pharmaceutically acceptable salts.

9. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the tricyclic compound according to any one of claims 1 to 7, its stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt.

10. Use of the tricyclic compound, its stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt according to any one of claims 1 to 7 in the preparation of a medicament for treating a disease or condition mediated by IRAK4; Preferably, the disease comprises an inflammatory disease, an autoimmune disease or a tumor; Preferably, the inflammatory disease is selected from Crohn's disease, ulcerative colitis, asthma, graft-versus-host disease, chronic obstructive pulmonary disease, atopic dermatitis, gout, gouty arthritis, conjunctivitis, hepatitis, chronic inflammatory lung disease, thyroiditis or interstitial cystitis; Preferably, the autoimmune disease is selected from Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, psoriasis, psoriatic arthritis, cryptopyrin-associated periodic syndrome, TNF receptor-associated periodic syndrome, multiple sclerosis, allergic rhinitis, scleroderma, dermatomyositis, vasculitis or nephritis; Preferably, the tumor is selected from lung cancer, breast cancer, prostate cancer, pancreatic cancer, kidney cancer, liver cancer, gastrointestinal cancer, cervical cancer, endometrial cancer, testicular cancer, genitourinary tract cancer, colorectal cancer, laryngeal cancer, skin cancer, bone cancer, head and neck tumors, sarcoma, brain tumor, glioblastoma, melanoma, multiple myeloma, lymphoma or leukemia.

Citation Information

Patent Citations

  • Imidazopyridine compound serving as IRAK4 degradation agent and application of imidazopyridine compound

    CN117777126A

  • IRAK degraders and uses thereof

    US20230101353A1

  • Compounds for targeting degradation of IRAK4 proteins

    US20240343733A1

  • Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (VHL)

    WO2019183523A1

  • Multi-protein degradation agent having imide skeleton

    WO2023116835A1